We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Lightlake Signs Agreement with Commercial Contract Manufacturer
News

Lightlake Signs Agreement with Commercial Contract Manufacturer

Lightlake Signs Agreement with Commercial Contract Manufacturer
News

Lightlake Signs Agreement with Commercial Contract Manufacturer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Lightlake Signs Agreement with Commercial Contract Manufacturer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Lightlake Therapeutics Inc. has announced that it has signed an agreement with a commercial contract manufacturer to commence production of its naloxone-based opioid overdose reversal treatment.

Lightlake expects that this manufacturer will be able to provide sufficient manufacturing capacity at cGMP production facilities to enable commercialization of its treatment on a global scale.

Naloxone is an injectable medicine that can rapidly reverse the overdose of prescription and illicit opioids. Lightlake has been developing a needleless intranasal delivery system for the delivery of naloxone that could widely expand its availability and use in preventing opioid overdose deaths, a public health problem of epidemic proportion in the United States.

"This is a significant milestone for Lightlake in forwarding our opioid overdose reversal treatment," said Dr. Roger Crystal, CEO of Lightlake. "We have been diligent in selecting our partner for the contract manufacturing process to best position us to produce a high quality treatment that can meet the requirements for FDA approval. We are confident that working with this partner will help us better serve the market need for a needleless treatment and provide us with significant competitive advantages."

"We are very pleased with the high quality of our partner involved in the contract manufacturing process," said Kevin Pollack, CFO of Lightlake. "Our partner has the capacity to produce significant quantities of our intranasal naloxone spray at a reasonable cost, which could facilitate our scaling up production to address a growing population of potential users of our treatment and should save more lives."

Advertisement